
BeiGene Ltd (ONC) Stock Forecast & Price Target
BeiGene Ltd (ONC) Analyst Ratings
Bulls say
BeOne Medicines is supported by a highly durable Brukinsa franchise, which generated about $1.25B in 2Q26 global sales, rose 31% year over year, and is tracking toward more than $5B in 2026 revenue, giving the company a dominant cash-generating core. The company also showed operating strength with 2Q26 total revenue of $1.7B, diluted EPS of $2.05, and $5.28B in cash and equivalents, while raising full-year guidance for revenue to $6.6B-$6.8B and operating income to $1.0B-$1.1B. Beyond Brukinsa, its more than 50 clinical-stage programs and multiple Phase 3 oncology readouts, including Tevimbra and sonrotoclax, create multiple paths for growth and de-risk the business over time.
Bears say
BeOne Medicines is viewed negatively because its investment case remains heavily dependent on Brukinsa, which accounted for 74% of total revenue in 2025, leaving the company exposed if growth slows or competitors gain share against AbbVie and AstraZeneca. The broader pipeline does not offset that concentration risk, since drug development is capital-intensive and uncertain, and the excerpt highlights that many programs fail in clinical development, face regulatory delays, or lack differentiated data needed to drive commercial success. Competitive pressure is also underscored by Sanofi’s CEA-targeted ADC setback in December 2023, showing how even promising oncology assets can fail to improve outcomes such as progression-free survival, which raises the risk of setbacks across BeOne’s more than 50 clinical trials.
This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.
BeiGene Ltd (ONC) Analyst Forecast & Price Prediction
Start investing in BeiGene Ltd (ONC)
Order type
Buy in
Order amount
Est. shares
0 shares